3-Nitropropionic acid animal model and Huntington' s disease

Albin, 1992, Alternative excitotoxic hypothesis, Neurol., 42, 733, 10.1212/WNL.42.4.733 Ankarcrona, 1995, Glutamate induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function, Neuron., 15, 961, 10.1016/0896-6273(95)90186-8 Beal, 1992, Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?, Ann. Neurol., 31, 119, 10.1002/ana.410310202 Beal, 1993, Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid, J. Neurosci., 13, 4181, 10.1523/JNEUROSCI.13-10-04181.1993 Borlongan, 1995, Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in rats, Brain Res. Bull., 36, 549, 10.1016/0361-9230(94)00242-S Borlongan, 1995, Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease, Brain Res., 697, 254, 10.1016/0006-8993(95)00901-2 Bossi, 1993, Age dependence of striatal neuronal death caused by mitochondrial dysfunction, Neuroreport., 4, 73, 10.1097/00001756-199301000-00019 Brouillet, 1993, Soc. Neurosci. Abstr., 19, 409 Brouillet, 1993, Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid, J. Neurochem., 60, 356, 10.1111/j.1471-4159.1993.tb05859.x Brouillet, 1994, Systemic or local administration of azide produces striatal lesions by a energy impairment-induced excitotoxic mechanism, Exp. Neural., 129, 175, 10.1006/exnr.1994.1159 Bruyn, 1968, Huntington's chorea, historical, clinical and laboratory synopsis, Handbook Clin. Neurol., 6, 298 Cox, 1989, Excitatory amino acid neurotoxicity at the N-methyl-d-aspartate receptor in cultured neurons: role of the voltage-dependent magnesium block, Brain Res., 499, 267, 10.1016/0006-8993(89)90774-9 Filloux, 1990, Nigral dopamine type-1 are reduced in Huntington's disease: a postmortem autoradiographic study using the [3H] SCH23390 and correlation with [3H] forskolin binding, Exp. Neurol., 110, 219, 10.1016/0014-4886(90)90033-O Gould, 1982, Basal ganglia degeneration, myelin alterations, and enzyme inhibition in mice induced by the plant toxin 3nitropropionic acid, Neuropathol. Appl. Neurobiol., 8, 377, 10.1111/j.1365-2990.1982.tb00306.x Gusella, 1983, A polymorphic marker genetically linked to Huntington's disease, Nature, 306, 234, 10.1038/306234a0 Hamilton, 1987, Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage, Acta Neuropathol., 72, 286, 10.1007/BF00691103 Hantraye, 1990, A primate model of Huntington's disease: behavioural and anatomical studies of unilateral excitotoxic lesions of the caudate-putaman in the baboon, Exp. Neurol., 108, 91, 10.1016/0014-4886(90)90014-J Isacson, 1985, Neural grafting in the rat model of Huntington's disease: progressive neuro-chemical changes after neostriatal ibotenate lesions and tissue grafting, Neurosci., 16, 799, 10.1016/0306-4522(85)90095-8 Koroshetz, 1992, Localized proton—NMR spectroscopy in patients with Huntinton's disease (HD) demonstrates abnormal lactate levels in occipital cortex: evidence for compromised metabolism in HD, Neurology, 42, 319 Koutouzis, 1994, Intrastriatal. 3-nitropropionic acid: a behavioral assessment, Neuroreport., 5, 2241, 10.1097/00001756-199411000-00009 Koutouzis, 1994, Systemic 3-nitropropionic acid: long effects on locomotor behavior, Brain Res. Rev., 64, 242, 10.1016/0006-8993(94)90085-X Koutouzis, 1994, Cell transplantation for central nervous system disorders, CRC Crit. Rev. Neurobiol., 3, 25 Ludolph, 1991, 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin, Can. J. Neurol. Sci., 18, 492, 10.1017/S0317167100032212 Martin, 1986, Huntington's disease: pathenogenesis and management, N. Engl. J. Med., 315, 1267, 10.1056/NEJM198611133152006 Mettler, 1972, Choreoathetosis and striopallidonigral necrosis due to sodium azide, Exp. Neurol., 34, 291, 10.1016/0014-4886(72)90175-6 Nishino, 1995, Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier, Neurosci. Lett., 186, 161, 10.1016/0304-3940(95)11311-J Novelli, 1988, Glutamate becomes neurorotoxic via the N-methyl-d-aspartate receptor when intracellular energies are reduced, Brain Res., 451, 205, 10.1016/0006-8993(88)90765-2 Sanberg, 1984, Scientific approaches to Huntington's disease, CRC Crit. Rev. Clin. Neurobiol., 1, 1 Shimano, 1995, Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle toms, Obesity Res., 3, 779, 10.1002/j.1550-8528.1995.tb00499.x Shoulson, 1986, Huntington's Disease, 1258 Stober, 1984, Bicaudate diameter — the most specific and simplified CT parameter in the diagnosis of Huntington's disease, Neuroradiol., 26, 25, 10.1007/BF00328198 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell., 72, 971, 10.1016/0092-8674(93)90585-E Zorumski, 1993, Excitotoxic neuronal damage and neuropsychiatric disorders, J. Pharm. Ther., 59, 145, 10.1016/0163-7258(93)90043-D